Search results
Results from the WOW.Com Content Network
The center is focused on detecting the genetic causes of prevalent childhood diseases including asthma, obesity, ADHD, autism, diabetes, inflammatory bowel disease, epilepsy, schizophrenia, and pediatric cancer, all of which are thought to potentially involve multiple, interacting genes within the body.
Cannabis use may be a contributory factor in the development of schizophrenia, potentially increasing the risk of the disease in those who are already at risk. [122] [123] [124] The increased risk may require the presence of certain genes within an individual. [22] Its use is associated with doubling the rate. [125]
Born: 1948 (age 76–77) Education: Miami University George Washington University (): Known for: Schizophrenia research NIMH CATIE study [1]: Children: 2: Awards: Lieber Prize for Schizophrenia Research from the National Association for Research in Schizophrenia and Affective Disorders
Within a year of its inception, researchers at the center and their international collaborators published a paper on their analysis of a collection of more than 7,000 genetic samples for schizophrenia. [3] The center later launched efforts to collect and sequence genetic samples for such conditions as bipolar disorder, autism spectrum disorders ...
RECOVER-2 is a confirmatory 4-week, randomized, double-blind, placebo-controlled, multicenter phase III clinical trial of 450 acute schizophrenia patients, where patients will receive brilaroxazine 30 mg, 50 mg, or placebo once daily. Completion is expected in Q2 2025 and brilaroxazine FDA new drug application (NDA) submission is expected in Q3 ...
Peter F. Buckley is an American psychiatrist and university administrator who focuses on the neurobiology and treatment of schizophrenia. [2] He received his medical degree from the University College Dublin School of Medicine in Ireland [3] and joined the Medical College of Georgia in 2000 as chair of the Department of Psychiatry and health behavior. [2]
Roluperidone (former developmental code names MIN-101, CYR-101, MT-210) is a 5-HT 2A and σ 2 receptor antagonist under development by Minerva Neurosciences for the treatment of schizophrenia.
Iclepertin (developmental code name BI 425809) is an investigational nootropic to enhance the cognition and functional capacity in schizophrenia developed by Boehringer Ingelheim. As of May 2020, it is in phase III of clinical trial under the code name CONNEX-3. [ 1 ]